JP Morgan Maintains Overweight on Insmed, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $36 to $55.
May 29, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Insmed and raises the price target from $36 to $55.
The increase in price target from $36 to $55 by a reputable analyst at JP Morgan is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100